社区药房高血压患者转诊全科实践的多因素分析
本研究基于2011–2012年英格兰新药服务数据,对131 419例开始新降压药治疗的患者进行多因素logistic回归分析,识别药房转诊至全科医生的相关因素。结果显示4.5%患者在开始新药2周内被转诊,患者报告副作用是最强预测因素(调整OR 11.60),α受体阻滞剂处方与转诊相关,而血管紧张素II受体拮抗剂则降低转诊风险。结论表明多数患者无需转诊,药师主导的高血压管理未显著增加医疗工作量。
要点
- 开始新降压药2周内,4.5%患者被社区药房转诊至全科医生。
- 患者报告副作用是最强转诊预测因素(调整OR 11.60,95%CI 10.85–12.41)。
- α受体阻滞剂处方增加转诊风险(调整OR 1.28),血管紧张素II受体拮抗剂降低风险(调整OR 0.89)。
核心结论
- 多数患者经药师随访无需转诊,患者报告副作用、药物相关担忧及药物类别影响转诊。
- 药师参与未显著增加医疗工作量,支持进一步发展药师主导的高血压干预。
研究设计与样本
- 多因素logistic回归分析,数据来自2011–2012年英格兰社区药房新药服务。
- 分析131 419例患者,纳入15个预测因素,分为患者报告因素、人口学因素和药物相关因素三类。
主要发现
- 患者平均年龄65岁(±13岁),85%为白人种族。
- 5895例(4.5%)患者在开始新降压药2周内被药师转诊至全科医生。
- 患者报告副作用最可能被转诊(调整OR 11.60,95%CI 10.85–12.41)。
- α受体阻滞剂处方与转诊相关(调整OR 1.28,95%CI 1.12–1.47)。
- 血管紧张素II受体拮抗剂处方者转诊可能性更低(调整OR 0.89,95%CI 0.80–0.99)。
临床怎么用
- 社区药房药师随访新降压药治疗患者时,应重点关注患者报告的副作用和药物相关担忧以决定是否转诊。
- 对于使用α受体阻滞剂的患者,药师可提高转诊警惕性;使用血管紧张素II受体拮抗剂的患者转诊风险较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The burden of hypertension in primary care is high, and alternative models of care, such as pharmacist management, have shown promise. However, data describing outcomes from routine consultations between pharmacists and patients with hypertension are lacking. AIM: To identify factors associated with referral of patients from pharmacies to general practice within the first 2 weeks of starting a new antihypertensive medication. DESIGN AND SETTING: Multivariate logistic regression conducted on data from community pharmacies in England. METHOD: Data were obtained from the New Medicine Service between 2011 and 2012. Analyses were conducted on 131 419 patients. In all, 15 predictors were included in the model, grouped into three categories: patient-reported factors, demographic factors, and medication-related factors. RESULTS: Mean patient age was 65 years (±13 years), and 85% of patients were of white ethnicity. A total of 5895 (4.5%) patients were referred by a pharmacist to a GP within the first 2 weeks of starting a new antihypertensive medication. Patients reporting side effects (adjusted odds ratio [OR] 11.60, 95% confidence interval [CI] = 10.85 to 12.41) were most likely to be referred. Prescriptions for alpha-blockers were associated with referral (adjusted OR 1.28, 95% CI = 1.12 to 1.47), whereas patients receiving angiotensin-II receptor blockers were less likely to be referred (adjusted OR 0.89, 95% CI = 0.80 to 0.99). CONCLUSION: Most patients were followed up by pharmacists without the need for referral. Patient-reported side effects, medication-related concerns, and the medication class prescribed influenced referral. These data are reassuring, in that additional pharmacist involvement does not increase medical workload appreciably, and support further development of pharmacist-led hypertension interventions.
引用
- Albasri A, Prinjha S, McManus RJ, et al. Hypertension referrals from community pharmacy to general practice: multivariate logistic regression analysis of 131 419 patients. Br J Gen Pract. 2018. PMID: 29970396. doi:10.3399/bjgp18X697925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。